Mercaptopurine and Emla drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mercaptopurine and Emla. Common interactions include lacunar infarction among females and febrile neutropenia among males.

The phase IV clinical study analyzes what interactions people who take Mercaptopurine and Emla have. It is created by eHealthMe based on reports of 45 people who take Mercaptopurine and Emla from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

45 people who take Mercaptopurine and Emla together, and have interactions are studied.

What is Mercaptopurine?

Mercaptopurine has active ingredients of mercaptopurine. It is often used in crohn's disease. eHealthMe is studying from 20,130 Mercaptopurine users for its effectiveness, alternative drugs and more.

What is Emla?

Emla has active ingredients of lidocaine; prilocaine. eHealthMe is studying from 4,653 Emla users for its effectiveness, alternative drugs and more.

Number of Mercaptopurine and Emla reports submitted per year:

Common Mercaptopurine and Emla drug interactions by gender *:

female:

Lacunar infarction
Neutropenia
Paronychia
Pulmonary embolism
Rash
Seizure like phenomena
Sinus tachycardia
Sinusitis
Tachycardia
Varicella virus test positive

male:

Febrile neutropenia
Abdominal pain
Agitation
Coagulopathy
Deep vein thrombosis
Dehydration
Drug hypersensitivity
Hypoalbuminaemia
Ischaemic cerebral infarction
Neutropenia

Common Mercaptopurine and Emla drug interactions by age *:

0-1:

n/a

2-9:

Pyrexia
Febrile neutropenia
Alanine aminotransferase increased
Aspartate aminotransferase increased
Blood bilirubin increased
Cough
Diarrhoea
Gamma-glutamyltransferase increased
Hyperglycaemia
Hyperkalaemia

10-19:

Pancreatitis
Pupils unequal
Radiation necrosis
Seizure
Transaminases increased
Weight increased
Abdominal pain
Alanine aminotransferase increased
Blood bilirubin increased
Nausea

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

n/a

Common conditions people have *:

Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 36 people, 80.00%
Pain: 9 people, 20.00%
Nausea (feeling of having an urge to vomit): 8 people, 17.78%
Constipation: 8 people, 17.78%
Nausea And Vomiting: 6 people, 13.33%
Fever: 5 people, 11.11%
Stress And Anxiety: 3 people, 6.67%
Local Anaesthesia: 3 people, 6.67%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 6.67%
Headache (pain in head): 3 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Mercaptopurine and Emla?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.